Advice on navigating the interplay between clinical effectiveness, cost effectiveness and budget. With each orphan drug that enters the market, competition grows fiercer. Companies investing in orphan drugs are challenged with a boom & bust model that raises the stakes for each launch. Join our experienced presenter as we discuss advice on maintaining stable revenue streams in the orphan drug market.

Key Talking Points:

• A review of patterns of market maturity, with a specific focus on what market drivers led us to where we are today
• Forward-looking perspectives on strategic partnerships models to mitigate the boom and bust cycle in orphan drugs
• Answers and responses from a payer on what is close enough for clinical response
• Top financing mechanisms in reimbursement that maintain a stable cash flow cycle basis

Who Will Attend:

Directors, Senior Directors, Vice Presidents, and Senior Vice Presidents in pharmaceutical companies with the following areas of expertise:

• Commercialization
• Product Management
• Portfolio Management
• Pricing
• Reimbursement
• Strategic Partnerships